Výsledky vyhledávání - "Cytarabine/Etoposide"

High incidence rate of human herpesvirus 6 infection after Bendamustine, Cytarabine, Etoposide and Melphalan conditioning regimen: A monocentric and retrospective study

Autor: Noel Milpied, Reza Tabrizi, Kamal Bouabdallah, Simon Favre, Mathieu Sauvezie, Margot Robles, Stéphane Vigouroux, Gaëlle Labouré, Marie-Sarah Dilhuydy

Publikováno v: Archives of Clinical Nephrology. :038-043

Background: Following shortage of Carmustine, BeEAM regimen (Bendamustine, Etoposide, Cytarabine and Melphalan) was used before autologous transplant in relapsed/refractory lymphoma patients. We evaluated safety and efficacy of BeEAM compared to BEAM

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::138a1fe3ca258de76d9b769362f880cc
https://doi.org/10.17352/acn.000054

Zobrazit plný text záznamu

A Phase 2 study of bortezomib combined with either idarubicin/cytarabine or cytarabine/etoposide in children with relapsed, refractory or secondary acute myeloid leukemia: A report from the Children's Oncology Group

Autor: Jennifer J. Ballard, Alan S. Gamis, Gaye Jenkins, Franklin O. Smith, Gerrit Jan Schuurhuis, Terzah M. Horton, John P. Perentesis, Dianna S. Howard, Jeffrey A. Moscow, Todd A. Alonzo, Robert B. Gerbing, Angèle Kelder, Kathleen Adlard

Publikováno v: Pediatric Blood & Cancer. 61:1754-1760

Background This Phase 2 study tested the tolerability and efficacy of bortezomib combined with reinduction chemotherapy for pediatric patients with relapsed, refractory or secondary acute myeloid leukemia (AML). Correlative studies measured putative

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1a3bf46994c0cc4e9dbb18364b9ba586
https://doi.org/10.1002/pbc.25117

Zobrazit plný text záznamu

Population pharmacokinetics of cytarabine, etoposide, and daunorubicin in the treatment for acute myeloid leukemia

Autor: Morten K. Jensen, Per Hartvig Honoré, Lena E. Friberg, Mikkel Krogh-Madsen, Brendan C. Bender, Ove Juul Nielsen

Publikováno v: Cancer Chemotherapy and Pharmacology. 69:1155-1163

Interpatient variability in the pharmacokinetics (PK) of cytarabine, etoposide, and daunorubicin following body surface area-adjusted doses calls for studies that point to other covariates to explain this variability. The purpose of this study was to

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::307b08188cfc34da783923357773a083
https://doi.org/10.1007/s00280-011-1800-z

Zobrazit plný text záznamu

Safety and efficacy of high-dose ranimustine, cytarabine, etoposide and CY (MCVAC) regimen followed by autologous peripheral blood stem cell transplantation for high-risk diffuse large B-cell lymphoma

Autor: Shinichiro Okamoto, Takayuki Shimizu, Kenji Yokoyama, Yuiko Tsukada, Takehiko Mori, Jun Kato, Tomoki Ueda

Publikováno v: Bone Marrow Transplantation. 46:923-928

The efficacy of high-dose chemotherapy followed by autologous hematopoietic SCT for relapsed diffuse large B-cell lymphoma (DLBCL) has been reported, but an optimal conditioning regimen has not been determined. This study was conducted to evaluate th

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::80e6ea8b8b89dec27f2f01a5bd4aa662
https://doi.org/10.1038/bmt.2010.243

Zobrazit plný text záznamu

A phase I and pharmacologic study of idarubicin, cytarabine, etoposide, and the multidrug resistance protein (MDR1/Pgp) inhibitor PSC-833 in patients with refractory leukemia

Autor: Kenneth S. Bauer, Suhlan Wu, Tushar S. Garimella, Ming Tan, Douglas D. Ross, Judith E. Karp

Publikováno v: Leukemia Research. 29:263-271

This study was conducted to define the maximum tolerated dose (MTD), dose limiting toxicity (DLT), and pharmacokinetics of idarubicin when administered with and without the P-glycoprotein inhibitor PSC-833 in combination with cytarabine, and etoposid

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b445d85e695e3f347bf24917a8877e1
https://doi.org/10.1016/j.leukres.2004.07.002

Zobrazit plný text záznamu

Improved outcome of adult acute lymphoblastic leukaemia by moderately intensified chemotherapy which includes a ‘pre-induction’ course for rapid tumour reduction: preliminary results on 66 patients

Autor: RM Halie, G. W. van Imhoff, Edo Vellenga, H. Haaxma-Reiche, E. van den Berg, S Daenen, J. W. Smit, PJ De Kam

Publikováno v: British Journal of Haematology. 100:273-282

Sixty-six consecutive adult patients with acute lymphoblastic leukaemia (ALL) were treated with intensified chemotherapy which included a 'pre-induction' course of cytarabine (AraC) and etoposide (VP16) when the white blood cell count (WBC) was > or

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c6dbb3b1ebce9a4cdf6ccc6e14f22f3b
https://doi.org/10.1046/j.1365-2141.1998.00559.x

Zobrazit plný text záznamu

Improved outcome of adult acute lymphoblastic leukaemia by moderately intensified chemotherapy which includes a 'pre-induction' course for rapid tumour reduction

Publikováno v: British Journal of Haematology. 100(2):273-282

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dris___01423::12d6c47258e1afd9c2ed5a3819d27234
https://research.rug.nl/en/publications/972609ab-25a5-41da-9bd5-d41faf6de0e2

Zobrazit plný text záznamu

High Incidence of HHV-6 Infection Associated with Bendamustine, Cytarabine, Etoposide and Melphalan (BeEAM) Conditioning Regimen: Results of a Monocentric and Retrospective Study

Autor: Marie Sarah Dilhuydy, Krimo Bouabdallah, Noel-Jean Milpied, Margot Robles, Reza Tabrizi, Stephane Vigouroux, Gaëlle Labouré, Mathieu Sauvezie, Simon Favre

Publikováno v: Blood. 128:5817-5817

Background: Because of the disruption of BCNU (Carmustine) in France during several months, and based on the results reported by Visani and colleagues (Visaniet al, Blood 2011) Bendamustine has been used in combination with Etoposide, Cytarabine and

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a1a41f1a30959cc14ad047bee9aecfab
https://doi.org/10.1182/blood.v128.22.5817.5817

Zobrazit plný text záznamu

Idarubicin, Intermediate-Dose Cytarabine, Etoposide, and Granulocyte-Colony-Stimulating Factor Are Able to Recruit CD34+/HLA-DR-Cells During Early Hematopoietic Recovery in Accelerated and Chronic Phases of Chronic Myeloid Leukemia

Autor: A. M. Carella, R. Ferrero, Francesco Frassoni, M. Soracco, N. Pollicardo, Ester Pungolino, Marina Podestà

Publikováno v: Journal of Hematotherapy. 3:199-202

A group of 46 patients with chronic myelogenous leukemia (CML) [chronic phase (CP), 24 patients; accelerated phase (AP), 22 patients] ineligible for allogeneic bone marrow transplantation were given an intensive chemotherapy regimen consisting of ida

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::50c586c84a20ab4e55fbbe365501ca0d
https://doi.org/10.1089/scd.1.1994.3.199

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání